Sorafenib down-regulates c-IAP expression post-transcriptionally in hepatic carcinoma cells to suppress apoptosis

Biochemical and Biophysical Research Communications

Volumn 418, Issue 3, 2012, Pages 531-536

  Li, Xi feng ^a   Gong, Ren yan ^a   Wang, Meng ^a   Yan, Zhen lin ^a   Yuan, Bo ^a   Wang, Kui ^a   Shi, Le hua ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; C IAP1; Hepatocellular carcinoma; Sorafenib; Translational inhibition

Indexed keywords

CELLULAR INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 1; MESSENGER RNA; SORAFENIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INTERNAL RIBOSOME ENTRY SITE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN STABILITY; TRANSCRIPTION REGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DOWN-REGULATION; GENES, REPORTER; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LIVER NEOPLASMS; LUCIFERASES; MICE; MICE, INBRED C57BL; PROTEIN BIOSYNTHESIS; PYRIDINES; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 84862789108     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.01.060     Document Type: Article

References (26)

1. El-Serag H.B. Hepatocellular carcinoma. N. Engl. J. Med. 2011, 365(12):1118-1127.
2. Wilhelm S., Carter C., Lynch M., Lowinger T., Dumas J., Smith R.A., Schwartz B., Simantov R., Kelley S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 2006, 5(10):835-844.
3. Siegel A.B., Olsen S.K., Magun A., Brown R.S. Sorafenib: where do we go from here?. Hepatology 2011, 52(1):360-369.
4. Wan P.T., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., Jones C.M., Marshall C.J., Springer C.J., Barford D., Marais R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116(6):855-867.
5. Ricci M.S., Kim S.H., Ogi K., Plastaras J.P., Ling J., Wang W., Jin Z., Liu Y.Y., Dicker D.T., Chiao P.J., Flaherty K.T., Smith C.D., El-Deiry W.S. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell. 2007, 12(1):66-80.
6. Liu L., Cao Y., Chen C., Zhang X., McNabola A., Wilkie D., Wilhelm S., Lynch M., Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006, 66(24):11851-11858.
7. Zhang W., Konopleva M., Ruvolo V.R., McQueen T., Evans R.L., Bornmann W.G., McCubrey J., Cortes J., Andreeff M. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia. 2008, 22(4):808-818.
8. Blechacz B.R., Smoot R.L., Bronk S.F., Werneburg N.W., Sirica A.E., Gores G.J. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology 2009, 50(6):1861-1870.
9. Rahmani M., Davis E.M., Crabtree T.R., Habibi J.R., Nguyen T.K., Dent P., Grant S. The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol. Cell Biol. 2007, 27(15):5499-5513.
10. Deveraux Q.L., Leo E., Stennicke H.R., Welsh K., Salvesen G.S., Reed J.C. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J. 1999, 18(19):5242-5251.
11. Lu X., Lee M., Tran T., Block T. High level expression of apoptosis inhibitor in hepatoma cell line expressing Hepatitis B virus. Int. J. Med. Sci. 2005, 2(1):30-35.
12. Zender L., Spector M.S., Xue W., Flemming P., Cordon-Cardo C., Silke J., Fan S.T., Luk J.M., Wigler M., Hannon G.J., Mu D., Lucito R., Powers S., Lowe S.W. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006, 125(7):1253-1267.
13. Gyrd-Hansen M., Darding M., Miasari M., Santoro M.M., Zender L., Xue W., Tenev T., da Fonseca P.C., Zvelebil M., Bujnicki J.M., Lowe S., Silke J., Meier P. IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-kappaB as well as cell survival and oncogenesis. Nat. Cell Biol. 2008, 10(11):1309-1317.
14. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., de Oliveira A.C., Santoro A., Raoul J.L., Forner A., Schwartz M., Porta C., Zeuzem S., Bolondi L., Greten T.F., Galle P.R., Seitz J.F., Borbath I., Haussinger D., Giannaris T., Shan M., Moscovici M., Voliotis D., Bruix J. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359(4):378-390.
15. Cheng A.L., Kang Y.K., Chen Z., Tsao C.J., Qin S., Kim J.S., Luo R., Feng J., Ye S., Yang T.S., Xu J., Sun Y., Liang H., Liu J., Wang J., Tak W.Y., Pan H., Burock K., Zou J., Voliotis D., Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009, 10(1):25-34.
16. Hora C., Romanque P., Dufour J.F. Effect of sorafenib on murine liver regeneration. Hepatology 2011, 53(2):577-586.
17. Feng Y.X., Wang T., Deng Y.Z., Yang P., Li J.J., Guan D.X., Yao F., Zhu Y.Q., Qin Y., Wang H., Li N., Wu M.C., Wang H.Y., Wang X.F., Cheng S.Q., Xie D. Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. Hepatology 2011, 53(2):483-492.
18. Ou D.L., Shen Y.C., Yu S.L., Chen K.F., Yeh P.Y., Fan H.H., Feng W.C., Wang C.T., Lin L.I., Hsu C., Cheng A.L. Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res. 2010, 70(22):9309-9318.
19. Gyrd-Hansen M., Meier P. IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat. Rev. Cancer. 2010, 10(8):561-574.
20. Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V., Baldwin A.S. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998, 281(5383):1680-1683.
21. Yang Y., Fang S., Jensen J.P., Weissman A.M., Ashwell J.D. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 2000, 288(5467):874-877.
22. Clem R.J., Sheu T.T., Richter B.W., He W.W., Thornberry N.A., Duckett C.S., Hardwick J.M. C-IAP1 is cleaved by caspases to produce a proapoptotic C-terminal fragment. J. Biol. Chem. 2001, 276(10):7602-7608.
23. Van Eden M.E., Byrd M.P., Sherrill K.W., Lloyd R.E. Translation of cellular inhibitor of apoptosis protein 1 (c-IAP1) mRNA is IRES mediated and regulated during cell stress. RNA 2004, 10(3):469-481.
24. Rahmani M., Davis E.M., Bauer C., Dent P., Grant S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J. Biol. Chem. 2005, 280(42):35217-35227.
25. Kuo T.C., Lu H.P., Chao C.C. The tyrosine kinase inhibitor sorafenib sensitizes hepatocellular carcinoma cells to taxol by suppressing the HURP protein. Biochem. Pharmacol. 2011, 82(2):184-194.
26. Wang Z., Zhou J., Fan J., Qiu S.J., Yu Y., Huang X.W., Tang Z.Y. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma. Clin. Cancer Res. 2008, 14(16):5124-5130.